PET in oncology: Will it replace the other modalities?Carl K. Hoh, Michael E. Phelps, Daniel Silverman et al.|Seminars in Nuclear Medicine|1997Cited by 212
COMPARISON OF HELICAL COMPUTERIZED TOMOGRAPHY, POSITRON EMISSION TOMOGRAPHY AND MONOCLONAL ANTIBODY SCANS FOR EVALUATION OF LYMPH NODE METASTASES IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN RELAPSE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCERMarc Seltzer, Carl K. Hoh, Zoran L. Barbaric et al.|The Journal of Urology|1999Cited by 187
POSITRON EMISSION TOMOGRAPHY IN UROLOGICAL ONCOLOGYCarl K. Hoh, Arie S. Belldegrun, Marc Seltzer et al.|The Journal of Urology|1998Cited by 149
Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective.C. Yap, Johannes Czernin, Peter E. Valk et al.|PubMed|2001Cited by 114